At the news
? BEARISHIMPACT 7/10 COURT-RULING filed Jun 15, 2026 at 20:00 ET
The District of Delaware denied Guardant Health's post-trial motions in a patent infringement case brought by TwinStrand Biosciences and UW. The jury's 2023 verdict of willful infringement on two patents covering DNA sequencing technology stands, with $83.4M in damages based on a 6% royalty on $1.39B revenue base. The court denied enhanced damages and attorney fees but granted ongoing royalties at the same 6% rate plus supplemental damages and pre/post-judgment interest. Guardant's products and services (including Guardant360, Companion, Explore) were found to infringe.
- Jury awarded $83.4M in reasonable royalty damages (6% on $1.39B base including $106M services revenue) for willful infringement of claims on patented duplex consensus sequencing technology
- Court denied Guardant's motions for JMOL, new trial, and Rule 60(b) relief on all grounds, infringement findings across products (Guardant360) and services (Companion, Explore) are upheld
- Ongoing royalty set at 6% for adjudicated products post-verdict, plus supplemental damages at 6% for sales July 2023–Feb 2024, and pre-judgment interest at prime rate compounded quarterly
- Court declined to enhance damages under Read factors, case was close, no egregious litigation misconduct or concealment, but willfulness verdict was supported by evidence
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access